[vestigation of molecular factors determining BRAF-inhibitor sensitivity in solid tumors]

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Targeted therapies for V600 BRAF mutant solid tumors exist but treatment resistance is a significant challenge.
• Currently, no approved targeted therapies are available for non-V600 BRAF mutant tumors.
• Understanding resistance mechanisms in V600 BRAF mutant melanoma is crucial for developing alternative treatments.

Purpose of the Study:

• To investigate targeted therapy resistance mechanisms in V600 BRAF mutant melanoma.
• To explore potential therapeutic strategies for both V600 and non-V600 BRAF mutant tumors.
• To evaluate the efficacy of zoledronic acid and combined RAF/MEK inhibition.

Main Methods:

• Studied V600 BRAF mutant melanoma cell lines with varying PTEN expression.
• Investigated proliferation and migration in pre- and posttreatment isogeneic cell lines.
• Analyzed mRNA levels of MITF, FRA-1, and EGFR.
• Assessed combined inhibition of pan-RAF and MEK with sorafenib/AZ628 and selumetinib in non-V600 cell lines.

Main Results:

• Zoledronic acid more effectively inhibited proliferation and induced apoptosis in low-PTEN V600 BRAF mutant melanoma cells.
• Posttreatment V600 BRAF mutant melanoma cells exhibited increased invasiveness.
• Melanoma cell migration and proliferation negatively correlated with MITF and FRA-1 mRNA levels, respectively.
• Combined pan-RAF and MEK inhibition in non-V600 cell lines demonstrated superior efficacy in inhibiting cell growth, migration, and Erk activation, alongside increased apoptosis.

Conclusions:

• PTEN expression influences sensitivity to zoledronic acid in V600 BRAF mutant melanoma.
• Acquired resistance in V600 BRAF mutant melanoma can lead to a more invasive phenotype.
• Combined inhibition of pan-RAF and MEK represents a promising therapeutic approach for non-V600 BRAF mutant melanoma.